- Disease progression following 1 - 2 courses of HER2-targeted therapies with known clinical benefit i.e. trastuzumab, pertuzumab, lapatinib, ado-trastuzumab emtamsine or other investigational HER2 agents but NONE in the last 1 week prior to enrollment.